Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Hussain

Showing results (181-190 of 213) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2014
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancerAmir Goldkorn, Benjamin Ely, David I Quinn, et al.
International Journal of Cancer|September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trialAmir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
The quality of early relational health modifies the effect of early life stress on child emerging psychopathologyJennifer Warmingham, Andréane Lavallée, Paul Curtin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
The Journal of Urology|September 11, 2019
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public WorkshopChana Weinstock, Daniel Suzman, Paul Kluetz, et al.
The New England Journal of Medicine|April 5, 2013
Intermittent versus continuous androgen deprivation in prostate cancerMaha Hussain, Catherine M Tangen, Donna L Berry, et al.
Pediatric Research|April 21, 2022
Pandemic beyond the virus: maternal COVID-related postnatal stress is associated with infant temperamentCatherine Bianco, Ayesha Sania, Margaret H Kyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
Pageof 22

Showing results (181-190 of 213) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2014
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancerAmir Goldkorn, Benjamin Ely, David I Quinn, et al.
International Journal of Cancer|September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trialAmir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
The quality of early relational health modifies the effect of early life stress on child emerging psychopathologyJennifer Warmingham, Andréane Lavallée, Paul Curtin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
The Journal of Urology|September 11, 2019
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public WorkshopChana Weinstock, Daniel Suzman, Paul Kluetz, et al.
The New England Journal of Medicine|April 5, 2013
Intermittent versus continuous androgen deprivation in prostate cancerMaha Hussain, Catherine M Tangen, Donna L Berry, et al.
Pediatric Research|April 21, 2022
Pandemic beyond the virus: maternal COVID-related postnatal stress is associated with infant temperamentCatherine Bianco, Ayesha Sania, Margaret H Kyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
Pageof 22